

Damiano Rondelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/116472/publications.pdf>

Version: 2024-02-01

101
papers

1,626
citations

471509

17
h-index

302126

39
g-index

102
all docs

102
docs citations

102
times ranked

2323
citing authors

#	ARTICLE	IF	CITATIONS
1	Hematopoietic Stem Cell Transplantation in Nepal: International Partnership, Implementation Steps, and Clinical Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 268-275.	1.2	8
2	Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 579-587.	0.9	1
3	The need for locally generated data in haematology: a real-world experience of aplastic anaemia in Nepal. <i>British Journal of Haematology</i> , 2021, 192, e63-e65.	2.5	1
4	Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres. <i>British Journal of Haematology</i> , 2021, 192, 761-768.	2.5	41
5	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 267.e1-267.e5.	1.2	6
6	American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation. <i>Blood Advances</i> , 2021, 5, 3668-3689.	5.2	38
7	Chronic Opioid Use Is Highly Prevalent in Patients Undergoing Allogeneic Transplant and Impacts Long Term Outcomes. <i>Blood</i> , 2021, 138, 1823-1823.	1.4	2
8	Long-Term Cardiac Effects of Successful Non-Myeloablative HLA-Matched Sibling Transplants in Sickle Cell Disease. <i>Blood</i> , 2021, 138, 2898-2898.	1.4	0
9	Social and Demographic Factors Contributing to COVID-19 Vaccine Hesitancy in Patients with Hematologic Malignancies. <i>Blood</i> , 2021, 138, 841-841.	1.4	1
10	Chronic opioid use can be reduced or discontinued after haematopoietic stem cell transplantation for sickle cell disease. <i>British Journal of Haematology</i> , 2020, 191, e70-e72.	2.5	3
11	Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease. <i>Blood</i> , 2020, 136, 623-626.	1.4	26
12	PARP Inhibition Synergizes with Melphalan but Does not Reverse Resistance Completely. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1273-1279.	2.0	8
13	Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease. <i>PLoS ONE</i> , 2020, 15, e0229710.	2.5	14
14	Rapidly established telehealth care for blood cancer patients in Nepal during the COVID-19 pandemic using the free app Viber. <i>Ecancermedicalscience</i> , 2020, 14, ed104.	1.1	4
15	Title is missing!. , 2020, 15, e0229710.		0
16	Title is missing!. , 2020, 15, e0229710.		0
17	Title is missing!. , 2020, 15, e0229710.		0
18	Title is missing!. , 2020, 15, e0229710.		0

#	ARTICLE	IF	CITATIONS
19	The experience of adults with sickle cell disease and their HLA-matched adult sibling donors after allogeneic hematopoietic stem cell transplantation. <i>Journal of Advanced Nursing</i> , 2019, 75, 2943-2951.	3.3	6
20	Superior Survival in African American Patients Who Underwent Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e506-e511.	0.4	7
21	Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Sickle Cell Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 1565.	2.4	12
22	A Phase I/II Placebo-Controlled Randomized Pilot Clinical Trial of Recombinant Deoxyribonuclease (DNase) Eye Drops Use in Patients With Dry Eye Disease. <i>Translational Vision Science and Technology</i> , 2019, 8, 10.	2.2	22
23	Chromatin-Modifying Agent-Expanded Human Cord Blood Cells Display Reduced Allostimulatory Capacity. <i>Journal of Immunology</i> , 2019, 202, 2493-2501.	0.8	1
24	Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. <i>Lancet Haematology</i> , 2019, 6, e585-e596.	4.6	128
25	Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 855-860.	2.0	13
26	Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1142-1151.	2.0	48
27	Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings. <i>Blood</i> , 2019, 134, 2943-2943.	1.4	4
28	High Rates of Varicella Zoster Virus Antibody Seroconversion after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment. <i>Blood</i> , 2019, 134, 3081-3081.	1.4	4
29	Monitoring of Stored Hematopoietic Stem/Progenitor Graft Stability Program in a Single Institute. <i>Blood</i> , 2019, 134, 1968-1968.	1.4	2
30	Low Pre-Treatment Hemoglobin and Creatinine Clearance Correlate with Worse Overall Survival, Treatment-Related Mortality, and Regimen-Related Toxicities in Patients Undergoing a Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine and Melphalan. <i>Blood</i> , 2019, 134, 1980-1980.	1.4	1
31	Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant. <i>Blood</i> , 2019, 134, 3310-3310.	1.4	0
32	Development of a clinical hematology and stem cell transplantation program to provide state-of-the-art and cost-effective treatment to patients: a successful collaboration between a medical college in India and a leading medical university in the United States. <i>Blood Advances</i> , 2019, 3, 23-26.	5.2	2
33	Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1759-1765.	2.0	50
34	Bone Marrow Transplantation in Patients With Acute Leukemia In Cuba: Results From the Last 30 Years and New Opportunities Through International Collaboration. <i>Journal of Global Oncology</i> , 2018, 4, 1-7.	0.5	0
35	Drug Shortage Impacts Patient Receipt of Induction Treatment. <i>Health Services Research</i> , 2018, 53, 5078-5105.	2.0	7
36	Haploidentical Transplants: An Answer to Ethical Challenges on the Use of Preimplantation Donor Selection. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2167-2168.	2.0	1

#	ARTICLE	IF	CITATIONS
37	Blockade of TNF α to Improve Human CD34+ Cell Repopulating Activity in Allogeneic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2018, 9, 3186.	4.8	3
38	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. <i>Blood</i> , 2018, 132, 3032-3032.	1.4	6
39	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). <i>Blood</i> , 2018, 132, 577-577.	1.4	39
40	Health Care Utilization in Transplanted Versus Non-Transplanted Sickle Cell Disease Patients. <i>Blood</i> , 2018, 132, 313-313.	1.4	1
41	Survival Analysis in Patients of AML with Myelodysplasia Related Changes. <i>Blood</i> , 2018, 132, 5906-5906.	1.4	1
42	PARP Inhibitor Veliparib and Busulfan in a Xenograft Model of Myeloproliferative Neoplasm. <i>Blood</i> , 2018, 132, 3319-3319.	1.4	0
43	Collaborative Physician-Pharmacist Managed Multiple Myeloma Clinic Decreases Polypharmacy, Improves Guideline Adherence, and Prevents Treatment Delays. <i>Blood</i> , 2018, 132, 3542-3542.	1.4	0
44	Total Marrow and Lymphoid Irradiation to Rescue Refractory Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 536-537.	2.0	3
45	Strength Training to Enhance Early Recovery after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 659-669.	2.0	56
46	T Cell-Mediated Rejection of Human CD34+ Cells Is Prevented by Costimulatory Blockade in a Xenograft Model. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2048-2056.	2.0	4
47	Voriconazole-Induced Periostitis Mimicking Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. <i>Case Reports in Infectious Diseases</i> , 2016, 2016, 1-3.	0.5	1
48	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1197-1205.	2.0	17
49	Human hematopoietic CD34+ progenitor cells induce natural killer cell alloresponses via NKG2D activation. <i>Experimental Hematology</i> , 2016, 44, 14-23.e1.	0.4	1
50	Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 441-448.	2.0	111
51	Antifungal prophylaxis with Amphotericin B deoxycholate emulsified in lipids for acute myeloid leukemia patients treated in low economy countries. <i>Leukemia and Lymphoma</i> , 2016, 57, 474-476.	1.3	1
52	C75 Fatty Acid Synthesis (FAS) Inhibitor Has Potent Immunosuppressive Activity. <i>Blood</i> , 2016, 128, 2156-2156.	1.4	1
53	Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 2301-2301.	1.4	1
54	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. <i>Blood</i> , 2016, 128, 4271-4271.	1.4	5

#	ARTICLE	IF	CITATIONS
55	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2016, 128, 479-479.	1.4	32
56	Strength training to enhance early recovery after hematopoietic stem cell transplantation.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21687-e21687.	1.6	0
57	Strength training to enhance early recovery after hematopoietic stem cell transplantation.. <i>Journal of Clinical Oncology</i> , 2016, 34, 190-190.	1.6	0
58	Blood and Marrow Transplantation (BMT) in Acute Leukemia Patients in Cuba: Current Results and Future Opportunities through International Collaboration. <i>Blood</i> , 2016, 128, 5959-5959.	1.4	0
59	Cytopenia of Unknown Cause Post Allogeneic Stem Cell Transplant As a Predictor of Clinical Outcome. <i>Blood</i> , 2016, 128, 5761-5761.	1.4	0
60	In-Vitro and in-Vivo Synergistic Effect of Melphalan and Dual DNA Repair Inhibition in Multiple Myeloma. <i>Blood</i> , 2016, 128, 3301-3301.	1.4	0
61	A Focused Review of the Pathogenesis, Diagnosis, and Management of Tumor Lysis Syndrome for the Interventional Radiologist. <i>Seminars in Interventional Radiology</i> , 2015, 32, 231-236.	0.8	6
62	Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers. <i>Transfusion</i> , 2015, 55, 864-874.	1.6	14
63	Melphalan 200 Mg/m2 in Patients with Renal Impairment Is Associated with Increased Short Term Toxicity but Improved Response and Longer Treatment-Free Survival. <i>Blood</i> , 2015, 126, 1998-1998.	1.4	2
64	Dual DNA Damage Repair Inhibition Synergizes with Alkylator Chemotherapy for Myeloma and Acute Leukemia. <i>Blood</i> , 2015, 126, 2053-2053.	1.4	0
65	Preclinical Study for the Use of Abatacept to Prevent Rejection of Allogeneic CD34+ Cells in a Xenograft Model. <i>Blood</i> , 2015, 126, 4271-4271.	1.4	0
66	CCN2 - Exploring a New Biomarker in Myelofibrosis. <i>Blood</i> , 2015, 126, 4063-4063.	1.4	0
67	Clinical grade isolation of regulatory T cells from G-CSF mobilized peripheral blood improves with initial depletion of monocytes. <i>American Journal of Blood Research</i> , 2015, 5, 79-85.	0.6	3
68	Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 295-308.	2.0	305
69	Combination of Linear Accelerator-Based Intensity-Modulated Total Marrow Irradiation and Myeloablative Fludarabine/Busulfan: A Phase I Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2034-2041.	2.0	40
70	Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1274-1281.	2.0	18
71	MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. <i>Blood</i> , 2014, 124, 1183-1191.	1.4	135
72	LINAC-based intensity modulated total marrow irradiation (TMI) in addition to myeloablative fludarabine/IV busulfan conditioning prior to allogeneic stem cell transplant for high-risk hematologic malignancies: A phase I study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7045-7045.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America. <i>Blood</i> , 2013, 122, 768-768.	1.4	0
74	Co-Stimulatory Blockade With CTLA4-Ig Permits Transplantation Of Human Hematopoietic Stem Cells and HLA Incompatible T Cells In NOD/SCID β^3 Null (NSG) Mouse Model. <i>Blood</i> , 2013, 122, 1999-1999.	1.4	0
75	Genomic Signature Predicts Resistance To Busulfan In AML Cell Lines. <i>Blood</i> , 2013, 122, 3850-3850.	1.4	0
76	Myeloablative Fludarabine/ IV Busulfan Combined With Linac Based Intensity Modulated Total Marrow Irradiation (IM-TMI) In Allogeneic Stem Cell Transplant For High Risk Hematologic Malignancies: A Phase I Study. <i>Blood</i> , 2013, 122, 3285-3285.	1.4	0
77	Evaluation of Genotoxicity of Chromatin Modifying Agents Expanded Hematopoietic Graft in a Non-Human Primate Model.. <i>Blood</i> , 2012, 120, 2994-2994.	1.4	1
78	Role of Ethnicity in Clinical Outcomes of Patients with Ph-Negative Myeloproliferative Neoplasms. <i>Blood</i> , 2012, 120, 2076-2076.	1.4	12
79	Linac Based Total Marrow Irradiation and Myeloablative Chemotherapy In Allogeneic Stem Cell Transplantation for High Risk Patients.. <i>Blood</i> , 2010, 116, 4526-4526.	1.4	0
80	An in-Vivo Model of T Cell-Mediated Rejection of Human Hematopoietic CD34+ Stem Cells Using NOD/SCID β^3 null (NOG) Mice.. <i>Blood</i> , 2009, 114, 4474-4474.	1.4	0
81	In Vivo Treatment with Chromatin Modifying Agents Dramatically Increases Hematopoietic Stem Cell Numbers.. <i>Blood</i> , 2009, 114, 370-370.	1.4	0
82	Erythroblasts From Polycythemia Vera Patients Express the Dominant negative β^2 Isoform of the Glucocorticoid Receptor.. <i>Blood</i> , 2009, 114, 3899-3899.	1.4	5
83	Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2008, 141, 80-83.	2.5	58
84	Pulmonary extramedullary hematopoiesis in patients with myelofibrosis undergoing allogeneic stem cell transplantation. <i>Haematologica</i> , 2008, 93, 1593-1595.	3.5	20
85	Regulatory T Cells (Tregs) Can Be Isolated from G-CSF Mobilized PBSC after Monocyte Depletion and Inhibit Anti-Stem Cell T Cell Alloreactivity. <i>Blood</i> , 2008, 112, 3477-3477.	1.4	0
86	Philadelphia Chromosome- β^3 Negative Myeloproliferative Disorders: Biology and Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 64-72.	2.0	39
87	Pre-Transplant Test Dose vs. PK Studies during Conditioning Regimen To Target iv Busulfan in Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 3006-3006.	1.4	0
88	Regulatory T Cells Do Not Affect Human Hematopoietic Stem Cell Engraftment and Prevent T Cell Alloreactivity Against CD34+ Cells: A Preclinical Study.. <i>Blood</i> , 2007, 110, 4870-4870.	1.4	0
89	Characterization of Ex Vivo Expanded Cord Blood Graft Treated with Chromatin Modifying Agents for Potential Clinical Use.. <i>Blood</i> , 2007, 110, 4921-4921.	1.4	0
90	Cord Blood Nucleated Cells Induce Delayed Proliferative and Cytotoxic T Cell Alloreactivity.. <i>Blood</i> , 2006, 108, 5138-5138.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2005, 105, 4115-4119.	1.4	194
92	Studies of the Site and Distribution of CD34+ Cells in Idiopathic Myelofibrosis. <i>American Journal of Clinical Pathology</i> , 2005, 123, 833-839.	0.7	17
93	Studies of the Site and Distribution of CD34+ Cells in Idiopathic Myelofibrosis. <i>American Journal of Clinical Pathology</i> , 2005, 123, 833-839.	0.7	11
94	Impaired Alloantigen Presenting Activity of Cord Blood Nucleated Cells.. <i>Blood</i> , 2005, 106, 2203-2203.	1.4	0
95	African American Patients with Multiple Myeloma Have Prolonged Responses after Autologous Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 3131-3131.	1.4	0
96	Pretransplant Recipient Blood CD14+ preDC Levels Correlate with Increased Acute GVHD after Allogeneic PBSC Transplantation.. <i>Blood</i> , 2004, 104, 1226-1226.	1.4	1
97	The Proteasome Inhibitor PS-341 Induces Early Apoptosis of CD14+ Dendritic Cell (DC) Precursors and of CD1a+ Immature DC.. <i>Blood</i> , 2004, 104, 3451-3451.	1.4	1
98	Early Cross-Talk between Cord Blood CD34+ or CD133+ Cells and Allogeneic T Cells Regulates the Differentiation of Dendritic Cell Precursors.. <i>Blood</i> , 2004, 104, 2141-2141.	1.4	0
99	In-Vitro and In-Vivo Effects of Autologous and Allogeneic Lymphocytes on Human Cord Blood CD34+ Cell Function.. <i>Blood</i> , 2004, 104, 4962-4962.	1.4	0
100	Comparable Toxicity between Fludarabine/Full dose i.v. Busulfan and Fludarabine/Melphalan in Allogeneic PBSC Transplantation.. <i>Blood</i> , 2004, 104, 5032-5032.	1.4	0
101	Response to Therapy with Imatinib Mesylate in Patients with CML Is Poor in Non-Caucasian Patients.. <i>Blood</i> , 2004, 104, 2937-2937.	1.4	0